Mild asthma: Conundrums, complexities and the need to customize care.
Christine R JenkinsPublished in: Respirology (Carlton, Vic.) (2023)
Mild and moderate asthma cover a wide range of asthma presentations, phenotypes and symptom burden, and account for the majority of people with asthma worldwide. Mild asthma has been difficult to define because of its heterogeneity and wide spectrum of impact and outcomes, including being associated with severe exacerbations. Assessment of mild-moderate asthma is best made by combining asthma symptom control and exacerbation risk as the principle means by which to determine treatment needs. Incontrovertible evidence and guidelines support treatment initiation with anti-inflammatory medication, completely avoiding reliever-only treatment of mild asthma. Shared decision making with patients and a treatable traits approach will ensure that a holistic approach is taken to maximize patient outcomes. Most importantly, mild asthma should be regarded as a reversible, potentially curable condition, remaining in long-term remission through minimizing triggers and optimizing care.
Keyphrases
- chronic obstructive pulmonary disease
- lung function
- allergic rhinitis
- healthcare
- cystic fibrosis
- end stage renal disease
- palliative care
- chronic kidney disease
- rheumatoid arthritis
- type diabetes
- adipose tissue
- dna methylation
- gene expression
- risk factors
- systemic lupus erythematosus
- single cell
- genome wide
- ejection fraction
- disease activity
- clinical practice
- ulcerative colitis